- Home
- QLGN vs APRE Comparison
QLGN vs APRE Comparison
Compare QLGN & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- APRE
- Stock Information
- Founded
- QLGN 1996
- APRE 2006
- Country
- QLGN United States
- APRE United States
- Employees
- QLGN N/A
- APRE N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QLGN Health Care
- APRE Health Care
- Exchange
- QLGN Nasdaq
- APRE Nasdaq
- Market Cap
- QLGN 7.4M
- APRE 8.3M
- IPO Year
- QLGN N/A
- APRE 2019
- Fundamental
- Price
- QLGN $2.85
- APRE $1.40
- Analyst Decision
- QLGN
- APRE Strong Buy
- Analyst Count
- QLGN 0
- APRE 1
- Target Price
- QLGN N/A
- APRE $20.00
- AVG Volume (30 Days)
- QLGN 3.4M
- APRE 142.4K
- Earning Date
- QLGN 11-14-2025
- APRE 11-07-2025
- Dividend Yield
- QLGN N/A
- APRE N/A
- EPS Growth
- QLGN N/A
- APRE N/A
- EPS
- QLGN N/A
- APRE N/A
- Revenue
- QLGN N/A
- APRE $841,012.00
- Revenue This Year
- QLGN N/A
- APRE N/A
- Revenue Next Year
- QLGN N/A
- APRE N/A
- P/E Ratio
- QLGN N/A
- APRE N/A
- Revenue Growth
- QLGN N/A
- APRE N/A
- 52 Week Low
- QLGN $1.61
- APRE $1.31
- 52 Week High
- QLGN $8.81
- APRE $5.00
- Technical
- Relative Strength Index (RSI)
- QLGN 39.72
- APRE 42.88
- Support Level
- QLGN $2.66
- APRE $1.31
- Resistance Level
- QLGN $3.36
- APRE $1.49
- Average True Range (ATR)
- QLGN 0.55
- APRE 0.09
- MACD
- QLGN -0.17
- APRE -0.01
- Stochastic Oscillator
- QLGN 5.74
- APRE 23.68
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.